215 related articles for article (PubMed ID: 29935731)
21. Allowing innovative stem cell-based therapies outside of clinical trials: ethical and policy challenges.
Hyun I
J Law Med Ethics; 2010; 38(2):277-85. PubMed ID: 20579251
[TBL] [Abstract][Full Text] [Related]
22. Expanded access to investigational drugs in psychiatry: A systematic review.
Vermeulen SF; Polak TB; Bunnik EM
Psychiatry Res; 2023 Nov; 329():115554. PubMed ID: 37890403
[TBL] [Abstract][Full Text] [Related]
23. The 'false hope' argument in discussions on expanded access to investigational drugs: a critical assessment.
Hordijk M; Vermeulen SF; Bunnik EM
Med Health Care Philos; 2022 Dec; 25(4):693-701. PubMed ID: 35951276
[TBL] [Abstract][Full Text] [Related]
24. [Expanded Access in The Netherlands: prescribing unregistered medicine].
Polak TB; Cucchi DGJ; van Rosmalen J
Ned Tijdschr Geneeskd; 2021 Feb; 165():. PubMed ID: 33651496
[TBL] [Abstract][Full Text] [Related]
25. Individual patient treatment use of unapproved drugs: a new option for the seriously ill.
Simon LS; Green A
J Pain Palliat Care Pharmacother; 2010 Mar; 24(1):19-22. PubMed ID: 20345195
[TBL] [Abstract][Full Text] [Related]
26. Right-to-try laws and individual patient "compassionate use" of experimental oncology medications: A call for improved provider-patient communication.
Hoerger M
Death Stud; 2016; 40(2):113-20. PubMed ID: 26313583
[TBL] [Abstract][Full Text] [Related]
27. How Often Are Drugs Made Available Under the Food and Drug Administration's Expanded Access Process Approved?
McKee AE; Markon AO; Chan-Tack KM; Lurie P
J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S136-S142. PubMed ID: 28921646
[TBL] [Abstract][Full Text] [Related]
28. Charging for investigational drugs under an investigational new drug application. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172
[TBL] [Abstract][Full Text] [Related]
29. One Last Shot.
Berlin J
Tex Med; 2016 Jul; 112(7):33-8. PubMed ID: 27441422
[TBL] [Abstract][Full Text] [Related]
30. Right to experimental treatment: FDA new drug approval, constitutional rights, and the public's health.
Leonard EW
J Law Med Ethics; 2009; 37(2):269-79. PubMed ID: 19493072
[TBL] [Abstract][Full Text] [Related]
31. Implementation of 21st Century Cures Act Expanded Access Policies Requirements.
Kang S; Chang S; Ross JS; Miller JE
Clin Pharmacol Ther; 2021 Dec; 110(6):1579-1584. PubMed ID: 34431083
[TBL] [Abstract][Full Text] [Related]
32. Expanded access to investigational drugs.
Lurie P; Chan-Tack KM; Woodcock J
N Engl J Med; 2015 Apr; 372(15):1473. PubMed ID: 25853763
[No Abstract] [Full Text] [Related]
33. Expanded access to investigational drugs.
Sarpatwari A; Darrow JJ; Kesselheim AS
N Engl J Med; 2015 Apr; 372(15):1473-4. PubMed ID: 25853762
[No Abstract] [Full Text] [Related]
34. Compassionate use of unauthorized drugs: Legal regulations and ethical challenges.
Borysowski J; Górski A
Eur J Intern Med; 2019 Jul; 65():12-16. PubMed ID: 31036436
[TBL] [Abstract][Full Text] [Related]
35. An International Society for Cell & Gene Therapy working group short report on the future of expanded access to unapproved cell and gene therapies.
Zettler PJ; Ikonomou L; Levine AD; Turner L; Grilley B; Roxland BE
Cytotherapy; 2023 Jul; 25(7):712-717. PubMed ID: 37097267
[TBL] [Abstract][Full Text] [Related]
36. [Therapeutic uses of investigational drugs: research extension, compassionate use, and expanded access].
Goldim JR
Rev Panam Salud Publica; 2008 Mar; 23(3):198-206. PubMed ID: 18397586
[TBL] [Abstract][Full Text] [Related]
37. Oncology Expanded Access and FDA's Project Facilitate.
Scepura B; Chan M; Kim T; Boehmer J; Goldberg KB; Pazdur R
Oncologist; 2021 Oct; 26(10):e1880-e1882. PubMed ID: 34288259
[TBL] [Abstract][Full Text] [Related]
38. Before It's Too Late: Multistakeholder Perspectives on Compassionate Access to Investigational Drugs for Pediatric Patients With Cancer.
Gerasimov E; Donoghue M; Bilenker J; Watt T; Goodman N; Laetsch TW
Am Soc Clin Oncol Educ Book; 2020 May; 40():1-10. PubMed ID: 32412804
[TBL] [Abstract][Full Text] [Related]
39. Comparative Assessment of Non-trial Access to Investigational Medical Products in the U.S. and Japan.
Nakada H; Folkers KM; Takashima K
Ther Innov Regul Sci; 2021 Mar; 55(2):401-407. PubMed ID: 33098080
[TBL] [Abstract][Full Text] [Related]
40. US Food and Drug Administration Efforts to Facilitate the Use of Expanded Access Programs.
Kim T; Lurie P; Pazdur R
J Clin Oncol; 2015 Nov; 33(33):3979-80. PubMed ID: 26282656
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
